Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Croatia has been steadily growing in recent years, driven by a combination of customer preferences, local special circumstances, and underlying macroeconomic factors.
Customer preferences: Croatia has an aging population, with a significant portion of the population over the age of 65. This demographic tends to have a higher incidence of cancer, which has led to an increased demand for oncology drugs. Additionally, there is a growing trend towards personalized medicine, which has led to an increase in the use of targeted therapies and immunotherapies.
Trends in the market: One of the key trends in the Oncology Drugs market in Croatia is the increasing use of biosimilars. Biosimilars are less expensive versions of biologic drugs, which are used to treat cancer and other diseases. The use of biosimilars has been encouraged by the Croatian government, which has implemented policies to promote their use.Another trend in the market is the increasing use of combination therapies. Combination therapies involve the use of multiple drugs to treat cancer, and have been shown to be more effective than single-agent therapies. This trend has been driven by the increasing availability of new drugs and the growing understanding of the biology of cancer.
Local special circumstances: Croatia has a well-developed healthcare system, which provides universal access to healthcare services. The government has implemented policies to promote the use of generic drugs and biosimilars, which has helped to control healthcare costs. Additionally, there is a strong emphasis on cancer prevention and early detection in Croatia, which has led to a lower incidence of cancer compared to other countries in the region.
Underlying macroeconomic factors: The Croatian economy has been growing in recent years, driven by a combination of domestic demand and export-oriented industries. This has led to an increase in healthcare spending, which has helped to support the growth of the Oncology Drugs market. Additionally, Croatia is a member of the European Union, which has led to increased regulatory harmonization and the availability of new drugs in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
